:Talk:Ethyl eicosapentaenoic acid

{{edit}}

In the section on Cardiovascular diseases, diabetes following the first paragraph on the JELIS trial (ending with the phrase "...apparently through mechanisms independent from regulation of lipid metabolism") please add:

E-EPA has been approved by the FDA as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with very high triglycerides (VHTG) or severe hypertriglyceridemia, defined as TG ≥500 mg/dL.{{cite journal|last1=Weintraub|first1=HS|title=Overview of prescription omega-3 fatty acid products for hypertriglyceridemia|journal=Postgrad Med|date=2014|volume=126|pages=7-18|doi=10.3810/pgm.2014.11.2828|pmid=25387209|url=https://postgradmed.org/doi/10.3810/pgm.2014.11.2828|accessdate=20 April 2015}} When used to reduce very high triglycerides, the FDA-approved prescription E-EPA-only omega-3 fatty acid product was not associated with increases in LDL-C as compared to placebo in a clinical trial.{{cite journal|last1=Bays|first1=HE|last2=Ballantyne|first2=CM|last3=Kastelein|first3=JJ|last4=Isaacsohn|first4=JL|last5=Braeckman|first5=RA|last6=Soni|first6=PN|title=Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)|journal=Am J Cardiol|date=2011|volume=108|pages=682-690|doi=10.1016/j.amjcard.2011.04.015|pmid=21683321|accessdate=20 April 2015}} Prescription and supplement omega-3 fatty acid mixtures that contain docosahexaenoic acid (DHA) may elevate LDL-C.{{cite journal|last1=Jacobson|first1=TA|last2=Ito|first2=MK|last3=Macki|first3=KC|title=National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary|journal=J Clin Lipidol|date=2014|volume=8|pages=473-488|doi=10.1016/j.jacl.2014.07.007|pmid=25234560|url=http://www.lipidjournal.com/article/S1933-2874(14)00274-8/abstract}}

In the next paragraph, after the sentence ending "... and its cardiovascular complications, such as coronary artery disease and thickening of carotid arteries." please add the following sentences:

E-EPA has been shown to benefit endothelial function{{cite journal|last1=Kohashi|first1=K|last2=Nakagomi|first2=A|last3=Saiki|first3=Y|title=Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia|journal=Journal of Atherosclerosis and Thrombosis|date=2015|volume=21|issue=7|pages=12-29|doi=10.5551/jat.21022|pmid=24670266|url=https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_21022/_pdf|accessdate=20 April 2015}} and lipid peroxidation in humans{{cite journal|last1=Kelley|first1=NS|last2=Yoshida|first2=Y|last3=Erickson|first3=KL|title=Do n-3 polyunsaturated fatty acids increase or decrease lipid peroxidation in humans?|date=2014|volume=12|issue=8|pages=403-415|doi=10.1089/met.2014.0045|pmid=25045922|accessdate=20 April 2015}}, both of which are associated with atherosclerosis. Due to its potent antioxidant effects, E-EPA uniquely reduces lipoprotein oxidation in-vitro.{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=R|last3=Beauregard|first3=G|last4=Rowe|first4=J|title=Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]|journal=J Clin Lipidol|date=2011|volume=5|page=201}}{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=R|last3=Corbalan|first3=JJ|last4=Malinski|first4=T|title=Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract]|journal=J Am Coll Cardiol|date=2015|volume=65|page=A2139}}{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=RF|title=Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism|journal=Biochim Biophys Acta|date=2015|volume=1842|issue=2|pages=502-509|doi=10.1016/j.bbamem.2014.10.016|pmid=25449996|url=http://www.sciencedirect.com/science/article/pii/S0005273614003514|accessdate=20 April 2015}} Further, improvements in endothelial function, represented by changes in nitric oxide (NO) release, alone and in combination with statin, have been observed with E-EPA.{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=R|last3=Beauregard|first3=G|last4=Rowe|first4=J|title=Comparative lipid antioxidant effects of omega-3 fatty acids in combination with HMG-CoA reductase inhibitors [abstract]|journal=J Clin Lipidol|date=2011|volume=5|page=201}}{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=RF|last3=Corbalan|first3=J|last4=Malinski|first4=T|title=Combination treatment with eicosapentaenoic acid and atorvastatin active metabolite reverses endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. Presented at the Deuel Conference on Lipids, March 3-6, 2015, Monterey, California}} When tested in vitro in model membrane lipid vesicles, EPA, but not other TG-lowering agents tested in this model, inhibited the formation of cholesterol crystalline domains associated with atherosclerosis.{{cite journal|last1=Mason|first1=RP|last2=Jacob|first2=RF|title=Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism|journal=Biochim Biophys Acta|date=2015|volume=1842|issue=2|pages=502-509|doi=10.1016/j.bbamem.2014.10.016|pmid=25449996|url=http://www.sciencedirect.com/science/article/pii/S0005273614003514|accessdate=20 April 2015}}

{{reflist-talk}}

- — Preceding unsigned comment added by 5020QVRoad (talk • contribs) 13:27, 21 April 2015 (UTC)

• {{PMID|25387209}} is great. Using it. Jytdog (talk) 23:53, 31 March 2016 (UTC)
• {{PMID|25234560}} is good but {{PMID|26699442}} is better. Using that. Jytdog (talk) 02:37, 1 April 2016 (UTC)
• the rest appear to be primary sources or opinion pieces and not useful per WP:MEDRS Jytdog (talk) 02:55, 1 April 2016 (UTC)

Note - this article was not written per the community's standards for article about health - WP:MEDMOS for style and WP:MEDRS for sourcing, and I'm fixing it. There also was a lot of content in here about Eicosapentaenoic acid which is distinct from the subject of this article... and many of the sources were very old, and primary. i will build back up the Research section from recent reviews. Jytdog (talk) 21:13, 31 March 2016 (UTC)

See discussions at Talk:Omega-3 fatty acid about making all these fish oil/omega-3 articles make sense across Wikipedia. Am not going to restore "research" until that gets worked out, as the same content is already in a bunch of different articles. Jytdog (talk) 00:52, 1 April 2016 (UTC)

The subsection "Dietary supplements" is not relevant

to the topic. At least in the UShttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202057s019lbl.pdf, Vascepa is a prescription medication, so having this section could confuse the reader into thinking that it's a dietary supplement. I propose removing this section from this article, and potentially moving its contents to Omega-3_fatty_acid. Farzaneh (talk) 14:19, 15 August 2024 (UTC)

I went ahead and made the changes. Farzaneh (talk) 15:19, 29 August 2024 (UTC)

{{reflist-talk}}